Natural Health Trends Corp. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Natural Health Trends is an international direct-selling and e-commerce company selling NHT Global personal care, wellness and quality-of-life products. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $10.5 million | $13.4 million | $22.4 million | $24.9 million |
| Gross profit / margin | $7.8 million / 74.6% | $10.0 million / 74.6% | $16.7 million / 74.5% | $18.6 million / 74.7% |
| Operating income (loss) | $(0.7) million | $0.2 million | $(1.1) million | $(0.2) million |
| Net income (loss) | $(0.2) million | $0.2 million | $0.04 million | $0.08 million |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $(3.3) million | $(3.5) million |
- Q2 basic and diluted loss per share was $0.02; six-month earnings per share rounded to $0.00, versus $0.01 in the prior-year period.
- Operating expenses were $8.6 million in Q2, including $4.5 million of commissions and $4.1 million of selling, general and administrative expense. Other income was $0.4 million in Q2 and $1.1 million for the six months, primarily due to higher interest earned on cash equivalents.
- Cash and cash equivalents were $61.6 million at June 30, 2023, down from $69.7 million at December 31, 2022. Current assets were $69.9 million and current liabilities $21.5 million; the company reported a 3.2:1 current ratio and $48.4 million of working capital.
- The filing reports no borrowings or conventional debt balance. Operating lease liabilities totaled $3.7 million, and income taxes payable totaled $9.0 million, including $5.1 million noncurrent.
Changes versus the prior comparable period
- Q2 sales fell 21% year over year; six-month sales fell 10%. Hong Kong sales declined 22% in Q2 and accounted for 79% of quarterly sales. Substantially all Hong Kong revenue is from products delivered to members in China.
- Management attributed much of the reported Hong Kong sales decline to timing and deferred revenue: deferred revenue increased $1.2 million in Q2 2023, compared with a $1.4 million decrease in Q2 2022. Management said Q2 order volume was comparable year over year despite tepid consumer sentiment in China.
- Gross margin was broadly stable. Q2 commissions were 42.9% of sales versus 43.2%; six-month commissions were 42.5% versus 42.2%. Q2 SG&A increased to $4.1 million from $4.0 million.
- The company had 36,730 active members at June 30, down from 38,660 at December 31, 2022 and 43,020 a year earlier. Six-month operating cash use remained substantial, though it improved by $0.2 million year over year; management said cash use excluding repatriation-tax payments improved by $1.6 million.
- Cash decreased $8.1 million in the first half, reflecting operating cash use, $4.6 million in dividends paid and other movements. The company declared $0.20 per-share dividends in each of the first two quarters.
Outlook, risks and notable items
- Management anticipates near-term financial performance will continue to be adversely affected. It says existing liquidity and operating cash flows should fund normal operations and commitments for the foreseeable future, while acknowledging that operating cash flow remains negative.
- The company said it expects to continue quarterly dividends of $0.20 per share for the foreseeable future, subject to Board discretion and financial condition. A further $0.20 dividend was declared July 31, payable August 25, 2023. The repurchase authorization had $21.9 million remaining at June 30; no specific future repurchase commitment was made.
- Hong Kong/China exposure is a central risk: Hong Kong represented 79% of Q2 sales, and the filing describes political, regulatory, consumer-sentiment and operational uncertainty in the region. The company does not hold a China direct-selling license; timing and success of any future application are uncertain.
- Other cited risks include member attrition, direct-selling and product regulation, foreign currency and geopolitical exposure, reliance on third-party manufacturers and logistics providers, and potential disruption from epidemics or other events. The filing states there were no material changes to the risk factors in the 2022 Form 10-K.
- The company reported no legal proceedings and no material changes in internal control over financial reporting; management concluded disclosure controls were effective at June 30, 2023.
Most important facts for investors to verify
- Whether the deferred revenue build converts into product shipments and recognized sales, and how much of the reported sales decline reflects timing rather than underlying demand.
- Whether member counts and Hong Kong/China sales stabilize, given the high geographic concentration and continuing market and regulatory uncertainty.
- Whether operating cash flow improves and remains adequate to support dividends, lease and tax obligations, and planned China investment.
- How cash and investment balances evolve, including the $3.8 million held in China subject to foreign currency controls and the $50.5 million of investments classified as cash equivalents.
- Whether the quarterly dividend and any future repurchases remain consistent with operating performance and liquidity.